国际瘤疾病分类,第四版 (ICD-O-4):一个概述
Ariana Znaor1, Brian Rous2, Gabrielle Goldman Levy3
1Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Cancer epidemiology
|January 23, 2026
概括
国际瘤学疾病分类第四版 (ICD-O-4) 引入了用于详细瘤分类的五位数组织学代码. 这次更新与ICD-11相协调,并提高了癌症注册数据的准确性.
科学领域:
- 在瘤学瘤学.
- 癌症登记科学 癌症登记科学
- 医疗信息学 医疗信息学
背景情况:
- 国际瘤疾病分类 (ICD-O) 对于编码瘤拓,形态,行为和癌症登记册中的等级至关重要.
- 即将发布的第四版 (ICD-O-4) 旨在改进瘤实体编码,并与国际疾病分类第11版 (ICD-11) 保持一致.
研究的目的:
- 根据用户反和瘤分类方面的进展,更新ICD-O形态编码系统.
- 为了提高癌症注册和研究的瘤编码的准确性和细节性.
主要方法:
- 国际癌症注册表协会 (IACR) 对癌症注册表的调查表明,对更新ICD-O-3.2形态学有强烈支持.
- 根据世卫组织瘤分类 (WCT) 第5版开发了ICD-O-4的beta版本,并由国际癌症研究机构 (IARC) 发布为公开咨询.
主要成果:
- ICD-O-4包含了第五个字母数字用于组织学代码,增强了层次编码.
- 关键的变化包括更新的组织学和行为代码 (例如,垂体腺瘤从 /1到 /3),新的地形代码 (例如,胃食道结C16.7),以及对胆道和门癌的精细代码.
- 对地形代码的可选额外数字提供了进一步的细节.
结论:
- ICD-O-4是与病理学家,流行病学家,公共卫生研究人员和癌症注册专业人员合作开发的.
- 五位数的组织学代码提供了详细的,分层的瘤编码.
- 更新的地形和行为代码反映了关于瘤病因,阶段和行为的当前知识,改善了癌症数据质量.
更多相关视频
07:31Efficient PAM-Less Base Editing for Zebrafish Modeling of Human Genetic Disease with zSpRY-ABE8e
Published on: February 17, 2023
1.6K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.8K
相关概念视频
Classification of Epithelial Tissues: Overview
19.8K
Epithelial tissues are classified according to the shape of the cells and the number of cell layers formed. Cell shapes can be squamous (flattened and thin), cuboidal (square-like, as wide as it is tall), or columnar (rectangular, taller than it is wide). Additionally, the nucleus shape helps identify the type of epithelial cells. Squamous cells have flattened disc-shaped nuclei, cuboidal cells have spherical nuclei, and columnar cells have elongated nuclei.
Based on the number of cell layers,...
Based on the number of cell layers,...
19.8K
Therapeutic Drug Monitoring: Overview and Classification
325
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
325
Parkinson's Disease: Overview
1.9K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.9K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Ischemic Heart Disease: Overview
3.0K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.0K
RNA Editing
9.8K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.8K
